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Introduction
Dabrafenib, trametinib, and Ipilimumab are each indi-
cated for treatment of patients (pts) with metastatic
melanoma (Dabrafenib+trametinib in BRAF V600
mutation–positive metastatic melanoma). Dabrafenib
and trametinib can be safely combined and prolong
progression-free survival compared with monotherapy.
Combining Dabrafenib+trametinib with the CTLA-4
antibody Ipi has the potential to improve treatment
outcomes, but the safety profile is unknown. A recent
report suggested caution in combining the BRAF inhi-
bitor vemurafenib (V) with Ipilimumab; V+Ipilimumab
resulted in G3 elevations of ALT in 6/10 pts leading to
study discontinuation (NEJM2013 368; 14). The pre-
sent study was designed to characterize the safety of
Dabrafenib±trametinib+Ipilimumab, select recom-
mended phase 2 doses (RP2Ds), and report efficacy.
Methods
Pts with stage IIIc/IV BRAF V600E /K mutation–posi-
tive MM and ≤1 prior treatments are eligible. Dose
escalation occurs in cohorts of 3-6 pts followed by
expansion (≤30 pts) at the RP2D. At data cutoff (Nov 8,
2013), 10 pts were enrolled: 4 received D+Ipi (doublet),
2 received D only (withdrawn before Ipi treatment), and
4 received D+T+Ipi (triplet).
Results
Median age of the 10 pts was 59.5 y (range, 32-75 y).
Doublet: D 150 mg bid + Ipi 3 mg/kg q3w × 4 doses
was well tolerated and selected as RP2D. No G3/4 ALT
elevations or dose-limiting toxicities (DLTs) were
observed. The most frequent adverse events (AEs; ≥2)
were chills, fatigue, hand-foot syndrome, pyrexia, and
maculopapular rash. Of 4 pts, 2 are ongoing and 2
stopped treatment (disease progression). Pts are cur-
rently being enrolled at this dose level in the expansion.
Triplet: At current doses (D 100 mg bid/T 1 mg qd+Ipi
3 mg/kg q3w × 4), 2 out of 7 patients developed G3
colitis complicated by perforation.The triplet combina-
tion enrollment was therefore stopped. The most fre-
quent AEs (≥2) were pyrexia, chills, arthralgia, insomnia,
and maculopapular rash. One pt had G4 renal insuffi-
ciency that reversed rapidly.
Conclusions
To date the combinations of D+Ipi and D+T+Ipi appear
to be tolerable and have not been associated with signif-
icant hepatotoxicity in MM, suggesting differences
between BRAF inhibitors when combined with Ipi.
However, combination of dabrafenib+trametinib+Ipili-
mumab was stopped early after 2 out of 7 patients
developed colon perforation soon after initiating Ipili-
mumab therapy.
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